Mariscotti Giovanna, Houssami Nehmat, Durando Manuela, Campanino Pier Paolo, Regini Elisa, Fornari Alberto, Bussone Riccardo, Castellano Isabella, Sapino Anna, Fonio Paolo, Gandini Giovanni
Department of Diagnostic Imaging and Radiotherapy, A. O. U. Città della Salute e della Scienza of Turin, Breast Imaging Service, Radiology - University of Turin, Via Genova 3, 10126, Torino, Italy,
Eur Radiol. 2015 Sep;25(9):2673-81. doi: 10.1007/s00330-015-3669-4. Epub 2015 Mar 27.
Preoperative breast magnetic resonance (MR) often generates additional suspicious findings needing further investigations. Targeted breast ultrasound (US) is the standard tool to characterize MR additional lesions. The purpose of this study is to evaluate the potential role of digital breast tomosynthesis (DBT) to characterize MR detected additional findings, unidentified at targeted breast US.
This prospective study included women who a) had biopsy-proven, newly diagnosed breast cancers detected at conventional 2D mammography and/or US, referred to breast MR for tumour staging; and b) had DBT if additional MR findings were not detected at targeted ('second look') US.
In 520 patients, MR identified 164 (in 114 women, 22%) additional enhancing lesions. Targeted US identified 114/164 (69.5%) of these, whereas 50/164 (30.5%) remained unidentified. DBT identified 32/50 of these cases, increasing the overall characterization of MR detected additional findings to 89.0% (146/164). Using DBT the identified lesions were significantly more likely to be malignant than benign MR-detected additional lesions (p = 0.04).
DBT improves the characterization of additional MR findings not identified at targeted breast US in preoperative breast cancer staging.
• Targeted US identified 114 of 164 (69.5%) additional enhancing lesions at preoperative breast MRI. • DBT identified a further 32 of the 50 lesions unidentified on targeted US. • DBT improved the characterization of additional MR findings for breast cancer staging.
术前乳腺磁共振成像(MR)常产生需要进一步检查的额外可疑发现。靶向乳腺超声(US)是对MR额外病变进行特征性描述的标准工具。本研究的目的是评估数字乳腺断层合成(DBT)对MR检测到的、在靶向乳腺US中未明确的额外发现进行特征性描述的潜在作用。
这项前瞻性研究纳入了以下女性:a)经活检证实、在传统二维乳腺X线摄影和/或US检查中新诊断出乳腺癌,因肿瘤分期而转诊至乳腺MR检查;b)如果在靶向(“二次检查”)US中未检测到MR额外发现,则进行DBT检查。
在520例患者中,MR识别出164个额外的强化病变(114名女性,占22%)。靶向US识别出其中的114/164(69.5%),而50/164(30.5%)仍未明确。DBT识别出了这些病例中的32/50,将MR检测到的额外发现的总体特征性描述提高到89.0%(146/164)。使用DBT,识别出的病变比良性MR检测到的额外病变更有可能是恶性的(p = 0.04)。
DBT可改善术前乳腺癌分期中靶向乳腺US未识别的MR额外发现的特征性描述。
• 靶向US在术前乳腺MRI中识别出164个额外强化病变中的114个(69.5%)。• DBT在靶向US未识别的50个病变中又识别出32个。• DBT改善了乳腺癌分期中MR额外发现的特征性描述。